[go: up one dir, main page]

ATE521609T1 - Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs - Google Patents

Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs

Info

Publication number
ATE521609T1
ATE521609T1 AT08737246T AT08737246T ATE521609T1 AT E521609 T1 ATE521609 T1 AT E521609T1 AT 08737246 T AT08737246 T AT 08737246T AT 08737246 T AT08737246 T AT 08737246T AT E521609 T1 ATE521609 T1 AT E521609T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
aminothiazolylpyrimidene
derivatives
compounds
Prior art date
Application number
AT08737246T
Other languages
English (en)
Inventor
Lynsie Almeida
Huiping Guan
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE521609T1 publication Critical patent/ATE521609T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08737246T 2007-05-04 2008-05-02 Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs ATE521609T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91596607P 2007-05-04 2007-05-04
PCT/GB2008/050322 WO2008135786A1 (en) 2007-05-04 2008-05-02 Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE521609T1 true ATE521609T1 (de) 2011-09-15

Family

ID=39620323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08737246T ATE521609T1 (de) 2007-05-04 2008-05-02 Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs

Country Status (7)

Country Link
US (2) US20100137398A1 (de)
EP (1) EP2152702B1 (de)
JP (1) JP2010526048A (de)
CN (1) CN101687863B (de)
AT (1) ATE521609T1 (de)
ES (1) ES2369596T3 (de)
WO (1) WO2008135786A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
EP2975027A1 (de) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamide als jak-kinasemodulatoren
EP2554544A1 (de) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
KR102019530B1 (ko) 2011-11-23 2019-09-06 포톨라 파마슈티컬스, 인코포레이티드 피라진 키나아제 저해제
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
AU2014249050B2 (en) 2013-03-12 2017-10-05 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
MX2017003463A (es) 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
WO1998044341A1 (de) * 1997-03-27 1998-10-08 Glatt Gmbh Verfahren zum überwachen und/oder steuern und regeln eines granulations-, agglomerations-, instantisierungs-, coating- und trocknungsprozesses in einer wirbelschicht oder einer bewegten schüttung durch bestimmung der produktfeuchte sowie lufttechnischer apparat zur durchführung des verfahrens
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
KR100896664B1 (ko) * 2000-09-15 2009-05-14 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE326462T1 (de) * 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
AU2002321910A1 (en) * 2001-08-03 2003-02-17 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
EP1423380B1 (de) * 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
AU2003231880A1 (en) * 2002-05-30 2003-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
WO2004014382A1 (en) * 2002-07-29 2004-02-19 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2526908A1 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
PL1809624T3 (pl) * 2004-08-28 2014-03-31 Astrazeneca Ab Pochodne pirymidynosulfonoamidu jako modulatory receptora chemokinowego
ZA200704476B (en) * 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2008540335A (ja) * 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
CA2608009A1 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
DE102005025161A1 (de) * 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
EP1890703B1 (de) * 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidinverbindungen als chemokine rezeptoren inhibitoren
EP1948663B1 (de) * 2005-10-21 2011-09-14 Exelixis, Inc. Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2)
ES2391783T3 (es) * 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
JP5328361B2 (ja) * 2005-11-03 2013-10-30 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン

Also Published As

Publication number Publication date
JP2010526048A (ja) 2010-07-29
WO2008135786A1 (en) 2008-11-13
EP2152702B1 (de) 2011-08-24
EP2152702A1 (de) 2010-02-17
US20100204231A1 (en) 2010-08-12
ES2369596T3 (es) 2011-12-02
US20100137398A1 (en) 2010-06-03
CN101687863B (zh) 2012-09-12
CN101687863A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ATE445593T1 (de) Acetylenderivate
MA32505B1 (fr) 5-alcynyl-pyrimidines
ATE494926T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
TW200637817A (en) 5-aminoindole derivatives
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
ECSP088826A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
ATE440836T1 (de) Verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties